Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract C82: Role of influx and efflux transporters on gut absorption of selected tyrosine kinase inhibitors in a polarized gut epithelium model system.

Richard J. Honeywell, Christien Fatmawati, Marita Boeddha, Sarina Hitzerd, Ietje Kathmann, Elisa Giovannetti, Godefridus J. Peters

Mol Cancer Ther (2013) 12 (11_Supplement): C82.

https://doi.org/10.1158/1535-7163.TARG-13-C82

Published: 01 November 2013

View article titled, Abstract C82: Role of influx and efflux transporters on gut absorption of selected tyrosine kinase inhibitors in a polarized gut epithelium model system.

Journal Articles

Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

Amir Avan, Francesco Crea, Elisa Paolicchi, Niccola Funel, Elena Galvani, Victor E Marquez, Richard J. Honeywell, Romano Danesi, Godefridus J. Peters, Elisa Giovannetti

Mol Cancer Ther (2012) 11 (8): 1735–1746.

https://doi.org/10.1158/1535-7163.MCT-12-0037

Published: 08 August 2012

View article titled, Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

Includes: Supplementary data

Journal Articles

Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib

Elisa Giovannetti, Paolo A. Zucali, Godefridus J. Peters, Filippo Cortesi, Armida D'Incecco, Egbert F. Smit, Alfredo Falcone, Jacobus A. Burgers, Armando Santoro, Romano Danesi, Giuseppe Giaccone, Carmelo Tibaldi

Mol Cancer Ther (2010) 9 (3): 581–593.

https://doi.org/10.1158/1535-7163.MCT-09-0665

Published: 09 March 2010

View article titled, Association of Polymorphisms in <em>AKT1</em> and <em>EGFR</em> with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib

Journal Articles

Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines

Francesco Crea, Elisa Giovannetti, Filippo Cortesi, Valentina Mey, Sara Nannizzi, Marielle I. Gallegos Ruiz, Simona Ricciardi, Mario Del Tacca, Godefridus J. Peters, Romano Danesi

Mol Cancer Ther (2009) 8 (7): 1964–1973.

https://doi.org/10.1158/1535-7163.MCT-09-0027

Published: 14 July 2009

View article titled, Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines

Includes: Supplementary data

Journal Articles

Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells

Cecilia Ceresa, Elisa Giovannetti, Jens Voortman, Adrie C. Laan, Richard Honeywell, Giuseppe Giaccone, Godefridus J. Peters

Mol Cancer Ther (2009) 8 (5): 1026–1036.

https://doi.org/10.1158/1535-7163.MCT-08-0700

Published: 13 May 2009

View article titled, Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells

Journal Articles

Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins

Clara Lemos, Ietje Kathmann, Elisa Giovannetti, Jeroen A.M. Beliën, George L. Scheffer, Conceição Calhau, Gerrit Jansen, Godefridus J. Peters

Mol Cancer Ther (2009) 8 (3): 655–664.

https://doi.org/10.1158/1535-7163.MCT-08-0768

Published: 13 March 2009

View article titled, Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins

Journal Articles

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

Elisa Giovannetti, Valentina Mey, Sara Nannizzi, Giuseppe Pasqualetti, Mario Del Tacca, Romano Danesi

Mol Cancer Ther (2006) 5 (6): 1387–1395.

https://doi.org/10.1158/1535-7163.MCT-06-0004

Published: 03 July 2006

View article titled, Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

NARROW

Abstract C82: Role of influx and efflux transporters on gut absorption of selected tyrosine kinase inhibitors in a polarized gut epithelium model system.

Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib

Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines

Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells

Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

Email alerts

AACR Journals

Abstract C82: Role of influx and efflux transporters on gut absorption of selected tyrosine kinase inhibitors in a polarized gut epithelium model system.

Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib

Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines

Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells

Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only